secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aardvark Therapeutics, Inc. (AARD)
CIK:        0001774857
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210664
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aardvark Q1 net loss $21.6M; ARD-101/ARD-201 programs on voluntary pause
------------------------------------------------------------------------

- Net loss of $21.6M for Q1 2026 vs. $9.3M for Q1 2025, driven by higher R&D expenses.
- Cash, cash equivalents and ST investments at $91.2M (down from $110.0M Dec 31, 2025); runway into mid-2027.
- R&D expenses $16.6M (up $8.8M YoY) due to ARD-101 development and personnel costs.
- Voluntary pause on Phase 3 HERO trial and ARD-201 after reversible cardiac signals in a healthy volunteer study.
- Company working with FDA and expects to provide program guidance in Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/ck0001774857-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer